Blair William & Co. IL Raises Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Key Points

• Blair William & Co. IL increased its holdings in IQVIA Holdings by 38.0% in Q1, bringing its total shares to 7,925, valued at approximately $1.4 million.
• A significant majority of IQVIA's stock, 89.62%, is now owned by institutional investors, indicating strong market support.
• Analysts have mixed opinions on IQVIA, with HSBC downgrading the stock to a "hold" and Mizuho raising the target price to $225, reflecting varied outlooks on the company's future performance.

Blair William & Co. IL lifted its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 38.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,925 shares of the medical research company's stock after purchasing an additional 2,183 shares during the period. Blair William & Co. IL's holdings in IQVIA were worth $1,397,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. American National Bank & Trust acquired a new position in IQVIA in the first quarter valued at approximately $26,000. Golden State Wealth Management LLC raised its position in IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after purchasing an additional 130 shares during the period. AllSquare Wealth Management LLC acquired a new position in shares of IQVIA in the 1st quarter valued at $33,000. ST Germain D J Co. Inc. lifted its stake in shares of IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after purchasing an additional 76 shares during the last quarter. Finally, GKV Capital Management Co. Inc. purchased a new position in shares of IQVIA during the 4th quarter worth $39,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider directly owned 2,910 shares of the company's stock, valued at $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company's stock.

IQVIA Stock Up 2.2%

Shares of IQV stock traded up $4.17 during trading hours on Wednesday, reaching $190.08. 1,564,756 shares of the stock were exchanged, compared to its average volume of 2,002,457. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $252.88. The business's fifty day moving average is $167.92 and its two-hundred day moving average is $168.89. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a market capitalization of $32.31 billion, a P/E ratio of 27.51, a P/E/G ratio of 1.98 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. The business had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company's revenue was up 5.3% on a year-over-year basis. During the same period last year, the business earned $2.64 EPS. As a group, research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently issued reports on IQV. Mizuho boosted their price objective on shares of IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a report on Friday, July 25th. Hsbc Global Res downgraded shares of IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. Cowen reissued a "buy" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Finally, William Blair restated an "outperform" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Seven investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, IQVIA presently has a consensus rating of "Moderate Buy" and an average price target of $228.62.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.